natgillin/translations-raw huggingface dataset:
Patients taking Exforge HCT and driving vehicles or using machines should take into account that dizziness or weariness may occasionally occur.
Bolniki, ki jemljejo zdravilo Exforge HCT in vozijo motorna vozila ali uporabljajo stroje, morajo upoštevati, da se lahko občasno pojavi omotica ali utrujenost.
See also information under the heading “Do not take Exforge HCT”.
Glejte tudi informacije pod naslovom “Ne jemljite zdravila Exforge HCT”.
The recommended dose of Exforge HCT is one tablet per day, to be taken preferably in the morning.
Priporočeni odmerek zdravila Exforge HCT je ena tableta na dan, ki jo je najbolje vzeti zjutraj.
Children and adolescents The use of Exforge HCT in children and adolescents under 18 years of age is not recommended.
Otroci in mladostniki Pri otrocih in mladostnikih, ki so stari manj kot 18 let, uporaba zdravila Exforge HCT ni priporočena.
However, it is important to take into account that Exforge HCT may increase the hypotensive effect of other antihypertensive agents.
Pomembno pa je upoštevati, da zdravilo Exforge HCT lahko okrepi hipotenzivno delovanje drugih antihipertenzivnih zdravil.
There is no relevant use of Exforge HCT in the paediatric population (patients below age 18 years) for the indication of essential hypertension.
Zdravilo Exforge HCT ni namenjeno za uporabo pri pediatrični populaciji (pri bolnikih, mlajših od 18 let) za indikacijo esencialne hipertenzije.
To date there is no experience of the safe use of Exforge HCT in patients who have had a recent kidney transplantation.
Doslej ni izkušenj glede varnosti uporabe zdravila Exforge HCT pri bolnikih, ki jim je bila nedavno presajena ledvica.
Do not take Exforge HCT with grapefruit or grapefruit juice.
Zdravila Exforge HCT ne zaužijte skupaj z grenivko ali z grenivkinim sokom.
Exforge HCT is available in packs containing 14, 28, 30, 56, 90, 98 or 280 film-coated tablets, in multipacks of 280 tablets (comprising 4 cartons, each containing 70 tablets, or 20 cartons, each containing 14 tablets), and in hospital packs containing 56, 98 or 280 tablets in single perforated dose blisters.
Tablete Exforge HCT so na voljo v pakiranjih, ki vsebujejo 14, 28, 30, 56, 90, 98 ali 280 filmsko obloženih tablet, v skupnih pakiranjih z 280 tabletami (vsebujejo 4 škatle, od katerih vsaka vsebuje po 70 tablet ali 20 škatel, od katerih vsaka vsebuje po 14 tablet), in v bolnišničnih pakiranjih, ki vsebujejo 56, 98 ali 280 tablet v perforiranih pretisnih omotih za enkratni odmerek.
What Exforge HCT is and what it is used for
Kaj je zdravilo Exforge HCT in za kaj ga uporabljamo
If patients taking Exforge HCT suffer from dizziness, headache, fatigue or nausea the ability to react may be impaired.
Če se pri bolnikih, ki jemljejo zdravilo Exforge HCT, pojavlja omotica, glavobol, utrujenost ali navzea, je njihova zmožnost reagiranja lahko zmanjšana.
The dose of Exforge HCT should be based on the doses of the individual components of the combination at the time of switching.
Odmerek zdravila Exforge HCT mora ustrezati odmerkom posameznih učinkovin kombinacije v času prehoda.
Exforge HCT can be taken with or without food.
Zdravilo Exforge HCT je mogoče jemati s hrano ali brez nje.
Based on the existing data with the components, the use of Exforge HCT is not recommended during first trimester and contraindicated during the second and third trimester of pregnancy (see sections 4.3 and 4.4).
Glede na obstoječe podatke o posameznih sestavinah uporaba zdravila Exforge HCT ni priporočljiva v prvem trimesečju nosečnosti in je kontraindicirana v drugem in tretjem trimesečju nosečnosti (glejte poglavji 4.3 in 4.4).
In this active controlled clinical trial, the most common reasons for discontinuation of therapy with Exforge HCT were dizziness and hypotension (0.7%).
V tem aktivno kontroliranem kliničnem preskušanju sta bila najbolj pogosta razloga za prekinitev zdravljenja z zdravilom Exforge HCT omotičnost in hipotenzija
What Exforge HCT is and what it is used for What you need to know before you take Exforge HCT How to take Exforge HCT
Kaj je zdravilo Exforge HCT in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo Exforge HCT Kako jemati zdravilo Exforge HCT Možni neželeni učinki
In a variety of preclinical safety studies conducted in several animal species with amlodipine, valsartan, hydrochlorothiazide, valsartan/hydrochlorothiazide, amlodipine/valsartan and amlodipine/valsartan/hydrochlorothiazide (Exforge HCT), there was no evidence of systemic or target organ toxicity that would adversely affect the development of Exforge HCT for clinical use in humans.
V različnih predkliničnih študijah varnosti zdravila, ki so jih izvajali na več živalskih vrstah z amlodipinom, valsartanom in hidroklorotiazidom ter s kombinacijami valsartan/hidroklorotiazid, amlodipin/valsartan in amlodipin/valsartan/hidroklorotiazid (z zdravilom Exforge HCT), ni bilo znakov za sistemsko toksično delovanje ali toksično delovanje na tarčne organe, ki bi predstavljali razloge proti razvijanju zdravila Exforge HCT za klinično uporabo pri ljudeh.
How to store Exforge HCT Contents of the pack and other information
Shranjevanje zdravila Exforge HCT Vsebina pakiranja in dodatne informacije
The amlodipine component of Exforge HCT inhibits the transmembrane entry of calcium ions into cardiac and vascular smooth muscle.
Amlodipin v zdravilu Exforge HCT zavira transmembranski vstop kalcijevih ionov v srčne in žilne gladke mišice.
If photosensitivity reaction occurs during treatment with Exforge HCT, it is recommended to stop the treatment.
Če med zdravljenjem z zdravilom Exforge HCT pride do fotosenzitivnostne reakcije, je priporočena prekinitev zdravljenja.
Clinically significant hypotension due to Exforge HCT overdose calls for active cardiovascular support, including frequent monitoring of cardiac and respiratory function, elevation of extremities, and attention to circulating fluid volume and urine output.
Klinično značilna hipotenzija zaradi prevelikega odmerka zdravila Exforge HCT zahteva srčnožilno podporo, vključno s pogostim nadziranjem delovanja srca in dihal, dviganjem udov ter kontrolo krožečega volumna tekočine in izločanja urina.
Elderly patients, particularly those taking the maximum dose of Exforge HCT (10 mg/320 mg/25 mg), should have their blood pressure checked regularly.
Starejšim bolnikom, zlasti tistim, ki uporabljajo najvišji odmerek zdravila Exforge HCT (10 mg/320 mg/25 mg), je treba redno meriti krvni tlak.
In sodium-depleted and/or volume-depleted patients, such as those receiving high doses of diuretics, symptomatic hypotension may occur after initiation of treatment with Exforge HCT.
Pri bolnikih s primanjkljajem natrija in/ali hipovolemijo, na primer pri bolnikih, ki prejemajo visoke odmerke diuretikov, se lahko po uvedbi zdravljenja z zdravilom Exforge HCT pojavi simptomatska hipotenzija.
The use of Exforge HCT during breastfeeding is not recommended.
Uporaba zdravila Exforge HCT med dojenjem ni priporočena.
Statistically greater proportions of patients achieved blood pressure control (<140/90 mmHg) with Exforge HCT (71%) compared to each of the three dual combination therapies (45-54%) (p<0.0001).
Krvni tlak je uspelo uravnati (<140/90 mmHg) statistično večjemu deležu bolnikov, ki so jemali zdravilo Exforge HCT (71 %) v primerjavi s tistimi, ki so jemali katero od treh kombinacij s po dvema zdraviloma (45-54 %) (p<0,0001).
If excessive hypotension occurs with Exforge HCT, the patient should be placed in the supine position and, if necessary, given an intravenous infusion of normal saline.
Če se med uporabo zdravila Exforge HCT pojavi čezmerna hipotenzija, je treba bolnika poleči in mu, če je potrebno, dati intravensko infuzijo fiziološke raztopine.
What you need to know before you take Exforge HCT
Kaj morate vedeti, preden boste vzeli zdravilo Exforge HCT
Exforge HCT is contraindicated in patients with hypercalcaemia and should only be used after correction of any pre-existing hypercalcaemia.
Zdravilo Exforge HCT je kontraindicirano pri bolnikih s hiperkalciemijo in ga je mogoče uporabljati šele po korekciji morebitne že prisotne hiperkalciemije.
Exforge HCT can be used by people aged 65 years and over at the same dose as for other adults and in the same way as they have already taken the three substances called amlodipine, valsartan and hydrochlorothiazide.
Ljudje, ki so stari 65 let ali več, lahko uporabljajo zdravilo Exforge HCT v enakih odmerkih kot drugi odrasli in na povsem enak način, kot so prej jemali tri učinkovine amlodipin, valsartan in hidroklorotiazid.
The safety of Exforge HCT has been evaluated at its maximum dose of 10 mg/320 mg/25 mg in one controlled short-term (8 weeks) clinical study with 2,271 patients, 582 of whom received valsartan in combination with amlodipine and hydrochlorothiazide.
Varnost zdravila Exforge HCT so ocenjevali pri uporabi njegovega najvišjega odmerka 10 mg/320 mg/25 mg, in sicer v eni kotrolirani kratkotrajni (8-tedenski) klinični študiji z 2.271 bolniki, od katerih jih je 582 prejemalo valsartan v kombinaciji z amlodipinom in s hidroklorotiazidom.
The safety profile of Exforge HCT presented below is based on clinical studies performed with Exforge HCT and the known safety profile of the individual components amlodipine, valsartan and hydrochlorothiazide.
Spodaj navedene varnostne lastnosti zdravila Exforge HCT se nanašajo na podatke iz študij z zdravilom Exforge HCT in na znane varnostne lastnosti njegovih posameznih sestavin amlodipina, valsartana in hidroklorotiazida.
You can take Exforge HCT with or without food.
Zdravilo Exforge HCT lahko vzamete s hrano ali brez nje.
This is because grapefruit and grapefruit juice can lead to an increase in the blood levels of the active substance amlodipine, which can cause an unpredictable increase in the blood pressure lowering effect of Exforge HCT.
Grenivka in grenivkin sok lahko namreč povzročita zvišanje koncentracije učinkovine amlodipina v krvi, kar lahko pripelje do nepredvidljivega povečanja učinka zdravila Exforge HCT pri zniževanju krvnega tlaka.
The rate and extent of absorption of amlodipine, valsartan and hydrochlorothiazide from Exforge HCT are the same as when administered as individual dosage forms.
Hitrosti in obsegi absorpcije amlodipina, valsartana in hidroklorotiazida se ne razlikujejo od tistih pri odmerjanju posameznih sestavin.
Frequency Exforge HCT
Pogostnost Exforge HCT
Furthermore, concomitant use of Exforge HCT and NSAIDs may lead to worsening of renal function and an increase in serum potassium.
Poleg tega lahko sočasna uporaba zdravila Exforge HCT in NSAIDs povzroča poslabšanje delovanja ledvic in zvišanje koncentracije kalija v serumu.
Due to the hydrochlorothiazide component, Exforge HCT is contraindicated for use in patients with anuria (see section 4.3) and in patients with severe renal impairment (glomerular filtration rate (GFR) <30 ml/min/1.73 m2) (see sections 4.3, 4.4 and 5.2).
Zaradi vsebnosti hidroklorotiazida je zdravilo Exforge HCT kontraindicirano za uporabo pri bolnikih z anurijo (glejte poglavje 4.3) in pri bolnikih s hudo okvaro ledvic (s hitrostjo glomerulne filtracije (GFR) <30 ml/min/1,73 m2) (glejte poglavja 4.3, 4.4 in 5.2).
No formal interaction studies with other medicinal products have been performed with Exforge HCT.
Formalnih študij medsebojnega delovanja zdravila Exforge HCT z drugimi zdravili niso izvedli.
Exforge HCT combines three antihypertensive compounds with complementary mechanisms to control blood pressure in patients with essential hypertension: amlodipine belongs to the calcium antagonist class and valsartan to the angiotensin II antagonist class of medicines and hydrochlorothiazide belongs to the thiazide diuretics class of medicines.
Zdravilo Exforge HCT vsebuje tri antihipertenzivne učinkovine s komplementarnimi mehanizmi delovanja za obvladanje krvnega tlaka pri bolnikih z esencialno hipertenzijo: amlodipin spada med zaviralce kalcijevih kanalčkov, valsartan med antagoniste angiotenzina II in hidroklorotiazid v skupino tiazidnih diuretikov.
The full blood pressure lowering effect was achieved 2 weeks after being on their maximal dose of Exforge HCT.
Do polnega učinka na zniževanje krvnega tlaka je prišlo po 2 tednih zdravljenja z najvišjimi odmerki zdravila Exforge HCT.
If hypokalaemia develops during hydrochlorothiazide therapy, Exforge HCT should be discontinued until stable correction of the potassium balance.
Če se hipokaliemija pojavi v času zdravljenja s hidroklorotiazidom, je treba uporabo zdravila Exforge HCT prekiniti, dokler ni ravnovesje kalija stabilno.
In the 8-week controlled clinical study, changes in laboratory parameters observed with the combination of Exforge HCT were minor and consistent with the pharmacological mechanism of action of the monotherapy agents.
V 8-tedenski kontrolirani klinični študiji so bile pri uporabi kombinacije v zdravilu Exforge HCT spremembe vrednosti laboratorijskih parametrov majhne in v skladu s farmakološkim načinom delovanja posameznih sestavin.
When switching eligible elderly hypertensive patients (see section 4.1) to Exforge HCT, the lowest available dose of the amlodipine component should be used.
Pri prehodu ustreznih starejših bolnikov s hipertezijo (glejte poglavje 4.1) na zdravilo Exforge HCT, je potrebno uporabiti najnižji razpoložljivi odmerek amlodipina.
The side effects reported with Exforge HCT or one of its three active substances (amlodipine, valsartan and hydrochlorothiazide) are listed below and may occur with the use of Exforge HCT.
Neželeni učinki, o katerih so poročali pri uporabi zdravila Exforge HCT ali pri uporabi katere od treh učinkovin (amlodipina, valsartana in hidroklorotiazida), so navedeni spodaj in se lahko pojavijo pri uporabi zdravila Exforge HCT.
Since renal clearance of lithium is reduced by thiazides, the risk of lithium toxicity may presumably be increased further with Exforge HCT.
Ker tiazidi zmanjšajo ledvični očistek litija, uporaba zdravila Exforge HCT lahko predvidoma poveča toksične učinke litija.
Exforge HCT is used to treat high blood pressure in adult patients whose blood pressure is already controlled while taking amlodipine, valsartan and hydrochlorothiazide and who may benefit from taking one tablet containing all three substances.
Zdravilo Exforge HCT uporabljamo za zdravljenje visokega krvnega tlaka pri odraslih bolnikih, pri katerih je krvni tlak že urejen, kadar jemljejo amlodipin, valsartan in hidroklorotiazid in bi jim ustrezalo jemanje ene same tablete, ki vsebuje vse tri učinkovine.
Therefore, Exforge HCT is not recommended in this population.
Iz tega razloga uporaba zdravila Exforge HCT ni priporočena pri tej skupini bolnikov.
In the controlled trial of Exforge HCT, the counteracting effects of valsartan 320 mg and hydrochlorothiazide 25 mg on serum potassium approximately balanced each other in many patients.
V kontroliranem preskušanju zdravila Exforge HCT sta bila pri številnih bolnikih nasprotna učinka valsartana 320 mg in hidroklorotiazida 25 mg na koncentracijo kalija v serumu približno v ravnovesju.
In case severe or rapid hyponatraemia develops during Exforge HCT therapy, the treatment should be discontinued until normalisation of natraemia.
Če se v času zdravljenja z zdravilom Exforge HCT razvije huda ali nenadna hiponatriemija, je treba zdravljenje prekiniti do normalizacije vrednosti natrija v krvi.
When switching eligible hypertensive patients (see section 4.1) with hepatic impairment to Exforge HCT, the lowest available dose of the amlodipine component should be used.
Pri prehodu ustreznih bolnikov s hipertezijo (glejte poglavje 4.1) z jetrno okvaro na zdravilo Exforge HCT, je potrebno uporabiti najnižji razpoložljivi odmerek amlodipina.
If you take more Exforge HCT than you should If you have accidentally taken too many Exforge HCT tablets, talk to a doctor immediately.You may require medical attention.
Če ste vzeli večji odmerek zdravila Exforge HCT, kot bi smeli Če ste nehote vzeli preveč tablet zdravila Exforge HCT, se takoj posvetujte z zdravnikom.
If you get these symptoms, stop taking Exforge HCT and contact your doctor straight away.
Če opazite navedene simptome, takoj prenehajte jemati zdravilo Exforge HCT in obvestite svojega zdravnika.
Other medicines and Exforge HCT
Druga zdravila in zdravilo Exforge HCT
Following oral administration of Exforge HCT in normal healthy adults, peak plasma concentrations of amlodipine, valsartan and hydrochlorothiazide are reached in 6-8 hours, 3 hours, and 2 hours, respectively.
Po peroralni uporabi zdravila Exforge HCT pri normalnih zdravih odraslih doseže amlodipin najvišjo koncentracijo v plazmi v 6-8 urah, valsartan v 3 urah, hidroklorotiazid pa v 2 urah.
Exforge HCT tablets contain three substances called amlodipine, valsartan and hydrochlorothiazide.
Tablete Exforge HCT vsebujejo tri učinkovine: amlodipin, valsartan in hidroklorotiazid.
If Exforge HCT is used during breast-feeding, doses should be kept as low as possible.
Če bolnica uporablja zdravilo Exforge HCT v času dojenja, naj uporablja čim nižje odmerke.
Due to the hydrochlorothiazide component, Exforge HCT is contraindicated in symptomatic hyperuricaemia.
Zaradi vsebnosti hidroklorotiazida je pri bolnikih s simptomatsko hiperurikemijo uporaba zdravila Exforge HCT kontraindicirana.
There are no clinical studies on fertility with Exforge HCT.
Kliničnih študij glede plodnosti pri uporabi zdravila Exforge HCT ni.
The maximum recommended dose of Exforge HCT is 10 mg/320 mg/25 mg.
Najvišji priporočeni odmerek zdravila Exforge HCT je 10 mg/320 mg/25 mg.
If you forget to take Exforge HCT
Če ste pozabili vzeti zdravilo Exforge HCT
The reductions in systolic/diastolic blood pressure with Exforge HCT were 7.6/5.0 mmHg greater than with valsartan/hydrochlorothiazide, 6.2/3.3 mmHg greater than with amlodipine/valsartan, and 8.2/5.3 mmHg greater than with amlodipine/hydrochlorothiazide.
Znižanje sistoličnega/diastoličnega krvnega tlaka je bilo z zdravilom Exforge HCT za 7,6/5,0 mmHg večje kot s kombinacijo valsartan/hidroklorotiazid, za 6,2/3,3 mmHg večje kot s kombinacijo amlodipin/valsartan in za 8,2/5,3 mmHg večje kot s kombinacijo amlodipin/hidroklorotiazid.
When Exforge HCT is used in patients with renal impairment periodic monitoring of serum electrolytes (including potassium), creatinine and uric acid serum levels is recommended.
Pri bolnikih z okvaro ledvic, ki jemljejo zdravilo Exforge HCT, je priporočljivo periodično kontrolirati koncentracije elektrolitov v serumu (vključno s koncentracijami kalija), kreatinina in sečne kisline.
Concomitant use of Exforge HCT with aliskiren-containing products in patients with diabetes mellitus or renal impairment (GFR <60 ml/min/1.73 m2) (see sections 4.5 and 5.1).
Sočasna uporaba zdravila Exforge HCT in zdravil, ki vsebujejo aliskiren, je kontraindicirana pri bolnikih s sladkorno boleznijo ali z okvaro ledvic (GFR <60 ml/min/1,73m2) (glejte poglavji 4.5 in 5.1).
Exforge HCT is not recommended for mothers who are breast-feeding, and your doctor may choose another treatment for you if you wish to breast-feed, especially if your baby is a newborn, or was born prematurely.
Če želite dojiti, bo zdravnik za vas izbral drugo zdravilo, še posebno če je vaš otrok še novorojenček ali je bil rojen prezgodaj.
Exforge HCT should be used with caution to treat hypertension in patients with unilateral or bilateral renal artery stenosis or stenosis to a solitary kidney since blood urea and serum creatinine may increase in such patients.
Pri bolnikih z enostransko ali obojestransko stenozo ledvične arterije oz. s stenozo v primeru solitarne ledvice je pri zdravljenju hipertenzije z zdravilom Exforge HCT potrebna previdnost, saj pri takih bolnikih lahko pride do zvišanja koncentracij sečnine v krvi in kreatinina v serumu.
The following adverse reactions, listed by MedDRA System Organ Class and frequency, concern Exforge HCT (amlodipine/valsartan/HCT) and amlodipine, valsartan and HCT individually.
Spodaj navedeni neželeni učinki, ki so našteti po MedDRA razvrstitvi organskih sistemov in po pogostnosti, se nanašajo na zdravilo Exforge HCT (amlodipin/valsartan/hidroklorotiazid) in na amlodipin, valsartan in hidroklorotiazid posamezno.
Before switching to Exforge HCT patients should be controlled on stable doses of the monocomponents taken at the same time.
Preden bolnik preide na uporabo zdravila Exforge HCT, mora biti njegov krvni tlak urejen s sočasno uporabo stabilnih odmerkov posameznih učinkovin.
Due to the valsartan component, Exforge HCT is contraindicated in patients with severe hepatic impairment (see section 4.3).
Zaradi vsebnosti valsartana je zdravilo Exforge HCT kontraindicirano pri bolnikih s hudo okvaro jeter (glejte poglavje 4.3).
Do not use any Exforge HCT pack that is damaged or shows signs of tampering.
Zdravila Exforge HCT ne uporabljajte, če je ovojnina poškodovana ali opazite, da je bila že odprta.
Due to the valsartan component, Exforge HCT is contraindicated in patients with hepatic impairment (see sections 4.2 and 4.3).
Zaradi vsebnosti valsartana je zdravilo Exforge HCT kontraindicirano pri bolnikih z okvaro jeter (glejte poglavji 4.2 in 4.3).
At week 8, the mean reductions in systolic/diastolic blood pressure were 39.7/24.7 mmHg with Exforge HCT, 32.0/19.7 mmHg with valsartan/hydrochlorothiazide, 33.5/21.5 mmHg with amlodipine/valsartan, and 31.5/19.5 mmHg with amlodipine/hydrochlorothiazide.
Po 8 tednih je bilo povprečno znižanje sistoličnega/diastoličnega krvnega tlaka 39,7/24,7 mmHg z zdravilom Exforge HCT, 32,0/19,7 mmHg s kombinacijo valsartan/hidroklorotiazid, 33,5/21,5 mmHg s kombinacijo amlodipin/valsartan in 31,5/19,5 mmHg s kombinacijo amlodipin/ hidroklorotiazid.
In patients with mild to moderate hepatic impairment without cholestasis, the maximum recommended dose is 80 mg valsartan, and therefore, Exforge HCT is not suitable in this group of patients (see sections 4.2, 4.3 and 5.2).
Pri bolnikih z blago do zmerno okvaro jeter brez holestaze je najvišji priporočeni odmerek valsartana 80 mg, zato zdravilo Exforge HCT ni primerno za to skupino bolnikov (glejte poglavja 4.2, 4.3 in 5.2).
There is no experience on the use of Exforge HCT in pregnant women.
Z uporabo zdravila Exforge HCT pri nosečnicah ni nobenih izkušenj.
In patients with mild to moderate hepatic impairment without cholestasis, the maximum recommended dose is 80 mg valsartan and therefore Exforge HCT is not suitable in this group of patients (see sections 4.3, 4.4 and 5.2).
Pri bolnikih z blago do zmerno okvaro jeter brez holestaze je najvišji priporočeni odmerek valsartana 80 mg, zato zdravilo Exforge HCT ni primerno za to skupino bolnikov (glejte poglavja 4.3, 4.4 in 5.2).
Exforge HCT 5 mg/160 mg/12.5 mg film-coated tablets Exforge HCT 10 mg/160 mg/12.5 mg film-coated tablets Exforge HCT 5 mg/160 mg/25 mg film-coated tablets Exforge HCT 10 mg/160 mg/25 mg film-coated tablets Exforge HCT 10 mg/320 mg/25 mg film-coated tablets
Exforge HCT 5 mg/160 mg/12,5 mg filmsko obložene tablete Exforge HCT 10 mg/160 mg/12,5 mg filmsko obložene tablete Exforge HCT 5 mg/160 mg/25 mg filmsko obložene tablete Exforge HCT 10 mg/160 mg/25 mg filmsko obložene tablete Exforge HCT 10 mg/320 mg/25 mg filmsko obložene tablete
If any of the above applies to you, do not take Exforge HCT and talk to your doctor.
Če kaj od naštetega velja za vas, ne vzemite zdravila Exforge HCT, temveč povejte zdravniku.
Treatment with Exforge HCT should only start after correction of hypokalaemia and any coexisting hypomagnesaemia.
Zdravljenje z zdravilom Exforge HCT je mogoče uvesti šele po korekciji hipokaliemije in morebitne sočasne hipomagneziemije.